Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

NCT03427866 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Ruxolitinib

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]